演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

Reducing Incidence of Liver Cancer in Hepatitis C Carriers with Food Supplements

演題番号 : ISP-17

[筆頭演者]
David CP Chen:1 
[共同演者]
Christopher Duong Bui:2

1:Clinical Radiology, University of S. California, USA、2:Chris Bui Liver Disease Clinic, USA

 

Background: Liver cancer is the most common cancer in the world. Hepatitis B or C is the major cause of liver cancer. The total population of hepatitis C is 170 million. About 20 to 30 years later, 20-30% of hepatitis C carriers will develop to cirrhosis and liver cancer. High virus load is the key to predict liver cancer. Reducing the virus load is an important issues in management the hepatitis C carriers. Current therapy is interferon with Ribavirin and with about 30-50% cure rate. However, the side effects are severe such as general weakness, nausea, vomiting, low WBC and platelet and loss of hair. Therefore, searching for an alternative therapy is needed. We developed a combination of immune regulatory factors with herbs (Liver Strong), which can overcome the problems. This article reports our preliminary results.Materials and Methods: Twenty-one hepatitis C carriers were included. They took these supplements two capsules, two times a day. General conditions, blood liver function and virus counts were performed at day 0 and day 90. The results were evaluated with pair-Student's T test for statistics significance.Results: In 21 hepatitis C carriers, 15 of them (71%) were improved in general conditions, blood liver function and virus counts. For those improved cases, averagely about 90% reducing rate of virus counts in hepatitis C carriers in day 90. Discussion: Our animal study performed on mice showed increased natural killer cells killing activity and interferon-r. These two factors are important for suppressing and killing the virus within and outside the liver cell. With the success in animal study, we did a clinical trial of this supplement for hepatitis C carriers. The preliminary results are much encouraged with good reduction of virus counts without any side effect. The future plan will be a double blind study and isolated the key peptide within this compound.

前へ戻る